Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Reduced perlecan expression and accumulation in human carotid atherosclerotic lesions

Tran, Phan Kiet LU ; Agardh, Hanna E. ; Tran-Lundmark, Karin LU ; Ekstrand, Johan ; Roy, Joy ; Henderson, Bimma ; Gabrielsen, Anders ; Hansson, Göran K. ; Swedenborg, Jesper and Paulsson-Berne, Gabrielle , et al. (2007) In Atherosclerosis 190(2). p.264-270
Abstract

Heparan sulfate in the extracellular matrix of the artery wall has been proposed to possess anti-atherogenic properties by interfering with lipoprotein retention, suppression of inflammation, and inhibition of smooth muscle cell growth. Previously, the amount of heparan sulfate in atherosclerotic lesions from humans and animals has been shown to be reduced but the identity or identities of the heparan sulfate molecules being down regulated in this disease are not known. In this study, atherosclerotic lesions were retrieved from 44 patients undergoing surgery for symptomatic carotid stenosis. Normal iliac arteries from organ donors were used as controls. Analysis of the specimens by gene microarray showed a selective reduction in... (More)

Heparan sulfate in the extracellular matrix of the artery wall has been proposed to possess anti-atherogenic properties by interfering with lipoprotein retention, suppression of inflammation, and inhibition of smooth muscle cell growth. Previously, the amount of heparan sulfate in atherosclerotic lesions from humans and animals has been shown to be reduced but the identity or identities of the heparan sulfate molecules being down regulated in this disease are not known. In this study, atherosclerotic lesions were retrieved from 44 patients undergoing surgery for symptomatic carotid stenosis. Normal iliac arteries from organ donors were used as controls. Analysis of the specimens by gene microarray showed a selective reduction in perlecan gene expression, whereas, expression of the other heparan sulfate proteoglycans in the artery wall, agrin and collagen XVIII, remained unchanged. Expression of the large chondroitin sulfate proteoglycan, versican, also remained unchanged. Real-time PCR confirmed the decrease in perlecan gene expression and the unchanged expression of versican. The findings were supported by immunohistochemical analysis demonstrating a reduced accumulation of both perlecan core protein and heparan sulfate in carotid lesions. The study demonstrates a reduction of perlecan mRNA-expression and protein deposition in human atherosclerosis, which in part explains the low levels of heparan sulfate in this disease.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; and (Less)
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Atherosclerosis, Carotid stenosis, Heparan sulfate, Microarray, Perlecan
in
Atherosclerosis
volume
190
issue
2
pages
7 pages
publisher
Elsevier
external identifiers
  • scopus:33846050448
  • pmid:16620836
ISSN
0021-9150
DOI
10.1016/j.atherosclerosis.2006.03.010
language
English
LU publication?
no
id
bedc6afd-08f7-4e1e-a59f-1573df8e1350
date added to LUP
2019-07-01 22:17:28
date last changed
2024-06-12 23:42:39
@article{bedc6afd-08f7-4e1e-a59f-1573df8e1350,
  abstract     = {{<p>Heparan sulfate in the extracellular matrix of the artery wall has been proposed to possess anti-atherogenic properties by interfering with lipoprotein retention, suppression of inflammation, and inhibition of smooth muscle cell growth. Previously, the amount of heparan sulfate in atherosclerotic lesions from humans and animals has been shown to be reduced but the identity or identities of the heparan sulfate molecules being down regulated in this disease are not known. In this study, atherosclerotic lesions were retrieved from 44 patients undergoing surgery for symptomatic carotid stenosis. Normal iliac arteries from organ donors were used as controls. Analysis of the specimens by gene microarray showed a selective reduction in perlecan gene expression, whereas, expression of the other heparan sulfate proteoglycans in the artery wall, agrin and collagen XVIII, remained unchanged. Expression of the large chondroitin sulfate proteoglycan, versican, also remained unchanged. Real-time PCR confirmed the decrease in perlecan gene expression and the unchanged expression of versican. The findings were supported by immunohistochemical analysis demonstrating a reduced accumulation of both perlecan core protein and heparan sulfate in carotid lesions. The study demonstrates a reduction of perlecan mRNA-expression and protein deposition in human atherosclerosis, which in part explains the low levels of heparan sulfate in this disease.</p>}},
  author       = {{Tran, Phan Kiet and Agardh, Hanna E. and Tran-Lundmark, Karin and Ekstrand, Johan and Roy, Joy and Henderson, Bimma and Gabrielsen, Anders and Hansson, Göran K. and Swedenborg, Jesper and Paulsson-Berne, Gabrielle and Hedin, Ulf}},
  issn         = {{0021-9150}},
  keywords     = {{Atherosclerosis; Carotid stenosis; Heparan sulfate; Microarray; Perlecan}},
  language     = {{eng}},
  month        = {{02}},
  number       = {{2}},
  pages        = {{264--270}},
  publisher    = {{Elsevier}},
  series       = {{Atherosclerosis}},
  title        = {{Reduced perlecan expression and accumulation in human carotid atherosclerotic lesions}},
  url          = {{http://dx.doi.org/10.1016/j.atherosclerosis.2006.03.010}},
  doi          = {{10.1016/j.atherosclerosis.2006.03.010}},
  volume       = {{190}},
  year         = {{2007}},
}